Ma XH, Chen K, Wang S, Liu SY, Li DF, Mi YT, Wu ZY, Qu CF, Zhao XM. Bi-specific T1 positive-contrast-enhanced magnetic resonance imaging molecular probe for hepatocellular carcinoma in an orthotopic mouse model. World J Gastrointest Oncol 2022; 14(4): 858-871 [PMID: 35582105 DOI: 10.4251/wjgo.v14.i4.858]
Corresponding Author of This Article
Xin-Ming Zhao, MD, Chairman, Professor, Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. zhaoxinming@cicams.ac.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Ma XH, Chen K, Wang S, Liu SY, Li DF, Mi YT, Wu ZY, Qu CF, Zhao XM. Bi-specific T1 positive-contrast-enhanced magnetic resonance imaging molecular probe for hepatocellular carcinoma in an orthotopic mouse model. World J Gastrointest Oncol 2022; 14(4): 858-871 [PMID: 35582105 DOI: 10.4251/wjgo.v14.i4.858]
Xiao-Hong Ma, Shuang Wang, Deng-Feng Li, Yong-Tao Mi, Xin-Ming Zhao, Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Kun Chen, Zhi-Yuan Wu, Chun-Feng Qu, State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
Si-Yun Liu, GE Healthcare (China), Beijing 100176, China
Author contributions: Ma XH, Qu CF, and Zhao XM designed the research; Ma XH, Liu SY, Chen K, Wu ZY, Li DF and Mi YT performed the research; Ma XH, Wang S and Liu SY contributed new reagents or analytic tools; Ma XH, Liu SY, and Chen K analyzed the data and wrote the paper.
Supported byPUMC Youth Fund, No. 2017320010; Chinese Academy of Medical Sciences (CAMS) Research Fund, No. ZZ2016B01; and Beijing HopeRun Special Fund of Cancer Foundation of China, No. LC2016B15.
Institutional animal care and use committee statement: This study was approved by the ethics committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of the paper.
Data sharing statement: No additional data is available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Corresponding author: Xin-Ming Zhao, MD, Chairman, Professor, Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. zhaoxinming@cicams.ac.cn
Received: April 28, 2021 Peer-review started: April 28, 2021 First decision: July 14, 2021 Revised: August 31, 2021 Accepted: March 14, 2022 Article in press: March 14, 2022 Published online: April 15, 2022 Processing time: 351 Days and 15.7 Hours
ARTICLE HIGHLIGHTS
Research background
Hepatocellular carcinoma (HCC) threated the human heavily. It is urgent to find an effective method to detect and diagnose the HCC early. Our previous study has already verified the efficiency of alpha-fetoprotein (AFP)/glypican-3 (GPC3)-double-antibody-labeled iron oxide magnetic resonance imaging (MRI) molecular probe in vitro.
Research motivation
We validated the effectiveness of a bi-specific probe for enhancing T1-weighted positive contrast to detect and diagnose the early-stage HCC in an orthotopic mouse model. It will provide the evidence for the human application.
Research objectives
To in vivo validate the effectiveness of a bi-specific probe for early detection and diagnosis of the early-stage HCC.
Research methods
We synthesized the single- and double-antibody-conjugated 5-nm ultra-small superparamagnetic iron oxide (USPIO) probes respectively. T1- and T2-weighted MRI were performed on the mouse model injection of the different probes at 12-, 24-, and 32-h. All the tumor samples were histologically analyzed.
Research results
The bi-specific probe was the most effective kind of the probes in our experiment.
Research conclusions
The bi-specific T1-positive contrast-enhanced MRI probe for HCC demonstrated increased specificity and sensitivity to diagnose early-stage HCC.
Research perspectives
The in vivo enhancement in imaging by the USPIO probes was likely dose-dependent and requires further investigation.
